CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lannett Company, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lannett Company, Inc. Bankruptcy Case Study!
1150 Northbrook Drive
Suite 155
Phone: (215) 333-9000p:215 333-9000 Trevose, PA  19053  United States Fax: (302) 636-5454f:302 636-5454
This company ceased filing statements with the SEC on 6/20/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20236/30/2022YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Patrick G.Lepore 67 7/1/2018 7/1/2017
Chief Executive Officer, Director Timothy C.Crew 61 1/18/2018 1/2/2018
Vice President, Chief Quality, IT and Operations Officer John M.Abt 57 12/1/2021 3/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Kremers Urban Pharmaceuticals Inc. 1101 C Avenue West Seymour IN United States
Silarx Pharmaceuticals, Inc. 1033 Stoneleigh Avenue Carmel NY United States
Cody Laboratories, Inc. 601 Yellowstone Ave Cody Wyoming United States

Business Names
Business Name
Cody Laboratories, Inc.
Kremers Urban Pharmaceuticals, Inc.
Lannett Company, Inc.
Lannett Company, Inc.
Silarx Pharmaceuticals, Inc.
Stoneleigh Realty, LLC

General Information
Outstanding Shares: 10,780,187 (As of 4/18/2023)
Shareholders: 202
Stock Exchange: OTC
Federal Tax Id: 230787699
Fax Number: (302) 636-5454
Email Address: finance@lannett.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024